• Je něco špatně v tomto záznamu ?

Translational Studies on the Potential of a VEGF Nanoparticle-Loaded Hyaluronic Acid Hydrogel

J. O'Dwyer, R. Murphy, A. González-Vázquez, L. Kovarova, M. Pravda, V. Velebny, A. Heise, GP. Duffy, SA. Cryan

. 2021 ; 13 (6) : . [pub] 20210522

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21017702

Grantová podpora
13/IA/1840 Science Foundation Ireland - Ireland
604531 Seventh Framework Programme

Heart failure has a five-year mortality rate approaching 50%. Inducing angiogenesis following a myocardial infarction is hypothesized to reduce cardiomyocyte death and tissue damage, thereby preventing heart failure. Herein, a novel nano-in-gel delivery system for vascular endothelial growth factor (VEGF), composed of star-shaped polyglutamic acid-VEGF nanoparticles in a tyramine-modified hyaluronic acid hydrogel (nano-VEGF-HA-TA), is investigated. The ability of the nano-VEGF-HA-TA system to induce angiogenesis is assessed in vivo using a chick chorioallantoic membrane model (CAM). The formulation is then integrated with a custom-made, clinically relevant catheter suitable for minimally invasive endocardial delivery and the effect of injection on hydrogel properties is examined. Nano-VEGF-HA-TA is biocompatible on a CAM assay and significantly improves blood vessel branching (p < 0.05) and number (p < 0.05) compared to a HA-TA hydrogel without VEGF. Nano-VEGF-HA-TA is successfully injected through a 1.2 m catheter, without blocking or breaking the catheter and releases VEGF for 42 days following injection in vitro. The released VEGF retains its bioactivity, significantly improving total tubule length on a Matrigel® assay and human umbilical vein endothelial cell migration on a Transwell® migration assay. This VEGF-nano in a HA-TA hydrogel delivery system is successfully integrated with an appropriate device for clinical use, demonstrates promising angiogenic properties in vivo and is suitable for further clinical translation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017702
003      
CZ-PrNML
005      
20210729104006.0
007      
ta
008      
210726s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics13060779 $2 doi
035    __
$a (PubMed)34067451
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a O'Dwyer, Joanne $u Drug Delivery & Advanced Materials Team, School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland $u Trinity Centre for Bioengineering, Trinity College Dublin (TCD), Dublin 2, Ireland
245    10
$a Translational Studies on the Potential of a VEGF Nanoparticle-Loaded Hyaluronic Acid Hydrogel / $c J. O'Dwyer, R. Murphy, A. González-Vázquez, L. Kovarova, M. Pravda, V. Velebny, A. Heise, GP. Duffy, SA. Cryan
520    9_
$a Heart failure has a five-year mortality rate approaching 50%. Inducing angiogenesis following a myocardial infarction is hypothesized to reduce cardiomyocyte death and tissue damage, thereby preventing heart failure. Herein, a novel nano-in-gel delivery system for vascular endothelial growth factor (VEGF), composed of star-shaped polyglutamic acid-VEGF nanoparticles in a tyramine-modified hyaluronic acid hydrogel (nano-VEGF-HA-TA), is investigated. The ability of the nano-VEGF-HA-TA system to induce angiogenesis is assessed in vivo using a chick chorioallantoic membrane model (CAM). The formulation is then integrated with a custom-made, clinically relevant catheter suitable for minimally invasive endocardial delivery and the effect of injection on hydrogel properties is examined. Nano-VEGF-HA-TA is biocompatible on a CAM assay and significantly improves blood vessel branching (p < 0.05) and number (p < 0.05) compared to a HA-TA hydrogel without VEGF. Nano-VEGF-HA-TA is successfully injected through a 1.2 m catheter, without blocking or breaking the catheter and releases VEGF for 42 days following injection in vitro. The released VEGF retains its bioactivity, significantly improving total tubule length on a Matrigel® assay and human umbilical vein endothelial cell migration on a Transwell® migration assay. This VEGF-nano in a HA-TA hydrogel delivery system is successfully integrated with an appropriate device for clinical use, demonstrates promising angiogenic properties in vivo and is suitable for further clinical translation.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Murphy, Robert $u Department of Chemistry, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland
700    1_
$a González-Vázquez, Arlyng $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland $u Trinity Centre for Bioengineering, Trinity College Dublin (TCD), Dublin 2, Ireland
700    1_
$a Kovarova, Lenka $u R&D Department, Contipro, Dolni Dobrouc 401, 561 02 Dolni Dobrouc, Czech Republic $u Faculty of Chemistry, Institute of Physical Chemistry, Brno University of Technology, Purkynova 464/118, 612 00 Brno, Czech Republic
700    1_
$a Pravda, Martin $u R&D Department, Contipro, Dolni Dobrouc 401, 561 02 Dolni Dobrouc, Czech Republic
700    1_
$a Velebny, Vladimir $u R&D Department, Contipro, Dolni Dobrouc 401, 561 02 Dolni Dobrouc, Czech Republic
700    1_
$a Heise, Andreas $u Department of Chemistry, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland $u SFI Centre for Research in Medical Devices (CURAM), National University of Ireland Galway (NUIG) and Royal College of Surgeons in Ireland (RCSI), Galway and Dublin 2, Ireland
700    1_
$a Duffy, Garry P $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland $u Trinity Centre for Bioengineering, Trinity College Dublin (TCD), Dublin 2, Ireland $u SFI Centre for Research in Medical Devices (CURAM), National University of Ireland Galway (NUIG) and Royal College of Surgeons in Ireland (RCSI), Galway and Dublin 2, Ireland $u SFI Research Centre for Advanced Materials and Bioengineering Research Centre (AMBER), National University of Ireland Galway (NUIG), Royal College of Surgeons in Ireland (RCSI) and Trinity College Dublin (TCD), Dublin 2, Ireland $u Nursing and Health Sciences, Anatomy and Regenerative Medicine Institute (REMEDI), School of Medicine, College of Medicine, National University of Ireland Galway (NUIG), Galway, Ireland
700    1_
$a Cryan, Sally Ann $u Drug Delivery & Advanced Materials Team, School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland $u Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland $u Trinity Centre for Bioengineering, Trinity College Dublin (TCD), Dublin 2, Ireland $u SFI Centre for Research in Medical Devices (CURAM), National University of Ireland Galway (NUIG) and Royal College of Surgeons in Ireland (RCSI), Galway and Dublin 2, Ireland $u SFI Research Centre for Advanced Materials and Bioengineering Research Centre (AMBER), National University of Ireland Galway (NUIG), Royal College of Surgeons in Ireland (RCSI) and Trinity College Dublin (TCD), Dublin 2, Ireland
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 13, č. 6 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34067451 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104005 $b ABA008
999    __
$a ind $b bmc $g 1676396 $s 1138144
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 6 $e 20210522 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a 13/IA/1840 $p Science Foundation Ireland $2 Ireland
GRA    __
$a 604531 $p Seventh Framework Programme
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Možnosti archivace